REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/13/2026
Back to search
Official data from USPTO
ANIMALCELLTHERAPIES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
49
Latest update
06/14/2026
Trademark type
Combined
Nice classes
1, 5, 42
Filing date
02/04/2016
Registration date
06/13/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/15/2024
Last transaction
06/14/2026
Responsible office
United States Patent and Trademark Office
Status code
705
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
02/17/2013
First use in commerce
02/17/2013
Drawing code
3
Owner type
03
Owner location
Escondido, CA, US
Examiner
KEAN, AMY C
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the words "ANIMALCELLTHERAPIES", with a profile of a dog's head shown in three parts, above the "A" in "ANIMAL".
Holders and representatives
Holders
Animal Cell Therapies, Inc.
Animal Cell Therapies, Inc.
Representatives
Jeffrey Sheriff Pillsbury Winthrop Shaw Pittman LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological tissuebloodstem cellsumbilical cords and placentas for scientific and medical research use; cells for scientificlaboratory or medical research; laboratory chemicalsan antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; stem cells for research or scientific research purposes
Class 5
Cells for medical or clinical use; Stem cells for medical or veterinary purposes; Pharmaceutical preparations for use in tissue engineered and cell based veterinary and medical therapies for use in the treatment of osteoarthritisneurologic conditionsinflammatory conditionsimmune- mediated conditionsendocrine diseaseschronic degenerative diseasesgastrointestinal diseases; Pharmaceutical preparations manufactured or modified by genetic engineering in the form of stem cells for veterinary and medical purposes; Pharmaceutical and veterinary preparationsgene therapy products in the form of stem cells for therapeutic medical use; Biochemical preparations namelypreparations for use in gene therapy for the treatment of osteoarthritisneurologic conditionsinflammatory conditionsimmune-mediated conditionsendocrine diseaseschronic degenerative diseasesgastrointestinal diseases; Orthobiologic preparationsbiologic preparations in the nature of stem cells to achieve symptomatic relief and cures from various orthopedic diseases
Class 42
Medical and scientific research services in the field of animal stem cells for researchdiagnosticclinical use; biopharmaceutical developmentresearch and evaluation services of stem cell-based therapeutics for the treatment of diseaseinjuries and disorders; consulting services in the fields of biotechnologypharmaceutical research and developmentlaboratory testingdiagnosticspharmacogenetics
Publications
History of USPTO decisions and trademark events.
49 publications found
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
11/15/2024
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
11/15/2024
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
11/12/2024
PC.D
PETITION TO DIRECTOR DISMISSED
11/01/2024
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
11/01/2024
REIN
REINSTATED
11/01/2024
APET
ASSIGNED TO PETITION STAFF
10/21/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
08/30/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/30/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/30/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/30/2024
TPDR
TEAS PETITION TO DIRECTOR RECEIVED
08/15/2024
NCS8
NOTICE OF CANCELLATION SEC. 8 EMAILED
08/10/2024
C8..
CANCELLED SEC. 8 (6-YR)
08/10/2024
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
12/12/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/17/2023
E815
TEAS SECTION 8 & 15 RECEIVED
05/22/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/05/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/05/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/05/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/13/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
06/13/2017
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/09/2017
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/08/2017
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/22/2017
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/21/2017
EX1G
SOU EXTENSION 1 GRANTED
04/21/2017
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/20/2017
IUAF
USE AMENDMENT FILED
04/11/2017
EXT1
SOU EXTENSION 1 FILED
04/11/2017
EEXT
SOU TEAS EXTENSION RECEIVED
04/11/2017
EISU
TEAS STATEMENT OF USE RECEIVED
04/11/2017
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/11/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/16/2016
PUBO
PUBLISHED FOR OPPOSITION
08/16/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/27/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/06/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
07/06/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/06/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
07/06/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/06/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/02/2016
GNRT
NON-FINAL ACTION E-MAILED
06/02/2016
CNRT
NON-FINAL ACTION WRITTEN
06/02/2016
DOCK
ASSIGNED TO EXAMINER
05/19/2016
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
02/11/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/10/2016
NWAP
NEW APPLICATION ENTERED
02/08/2016
Continuous trademark protection
Get notified about every new filing that threatens ANIMALCELLTHERAPIES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.